U.S. Emerging Psoriasis Therapeutics Markets

Published by: Frost & Sullivan

Published: Jun. 1, 2001

Table of Contents

• Executive Summary
  
  
  
  • Market Overview
    
  • Major Research Findings
    
  
  
• Total Market
  
  
  
  • Overview
    
  • Forecasts and Trends
    
  • Competitive Analysis
    
  • Strategic Recommendations
    
  • Frost & Sullivan Market Engineering Awards
    
  
  
• Monoclonal Antibodies
  
  
  
  • Overview
    
  • U.S. Emerging Monoclonal Antibody Psoriasis Market: Forecasts and Trends
    
  • U.S. Emerging Monoclonal Antibody Psoriasis Market: Competitive Analysis
    
  
  
• Other Emerging Products
  
  
  
  • Overview
    
  • Other Emerging Products in U.S. Psoriasis Market: Forecasts and Trends
    
  • Competitive Analysis
    
  
  

• Table of Figures
  
• Table of Charts
  

Abstract

Psoriasis affects more than seven million people in the United States. Although immunosuppresants have been used to treat psoriasis for some time, these drugs often subdue the entire immune system, sometimes causing serious side effects. As scientists begin to unravel the genetic and immunological mysteries of psoriasis, a new wave of immunotherapies are being developed that will target specific psoriasis-related immunological pathways without compromising the body's defense mechanisms.

This Frost & Sullivan research investigates the status of drugs in development and assesses their role in the future treatment regimen for psoriasis. It analyzes potential markets for monoclonal antibodies and for other emerging products. By discussing market drivers and restraints and by presenting accurate revenue forecasts, this report offers its users an important guide to the future of a largely untapped field.

Manufacturers Must Encourage Dermatologists to Utilize New Therapies

"Drug companies may find it challenging to persuade dermatologists to prepare their practices for some of these new products," says the research's author. Dermatologists are used to prescribing topical products. Few prescribe oral medications on a regular basis, administer injections, or manage intravenous infusions. Yet it is through these methods that new immunotherapies will be administered.

Dermatologists whose practices focus on lucrative cosmetic dermatology may also be reluctant to undertake medical procedures, especially if reimbursement is problematic. Dermatologists need to be trained and motivated to invest in the necessary equipment required to administer these new drugs. This report identifies challenges that participants will face and provides expert recommendations, empowering your company to overcome hurdles and overtake the competition.

Strategic Partnerships Could Help Small Firms Increase Market Share

"Many of the new psoriasis drugs are being developed by small biopharmaceutical companies that lack the resources to manage drug commercialization," says the author. Often these companies have built up an expertise in a specific pharmaceutical sector but are unfamiliar with psoriasis markets. For many of these companies, the answer might be to partner with larger drug firms, which can provide financial assistance for adequate product development and commercialization. This study surveys the competitive field and pinpoints winning strategies, helping your company develop an effective business plan.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.